D
Septerna, Inc. SEPN
$26.17 -$1.45-5.25% NASDAQ
Recommendation
Prev Close
$26.17
Volume
22
Avg Vol (90D)
301,833
Market Cap
$1.17B
Dividend & Yield
--
52-Week Range
$4.17 - $29.74
P/E (TTM)
--
EPS (TTM)
-$1.51
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
10/15/2025 - MarketBeat
Septerna (NASDAQ:SEPN) Trading Down 5.7% - What's Next?
11/26/2025 - MarketBeat
NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes
11/26/2025 - Zacks Investment Research
Septerna, Inc. $SEPN Shares Purchased by Universal Beteiligungs und Servicegesellschaft mbH
11/26/2025 - MarketBeat
Septerna (NASDAQ:SEPN) Hits New 1-Year High - Here's What Happened
11/26/2025 - MarketBeat
Septerna to Participate in 8th Annual Evercore Healthcare Conference
11/25/2025 - GuruFocus
Septerna to Participate in 8th Annual Evercore Healthcare Conference
11/25/2025 - Globe Newswire
Septerna's Novo Partnership Begins To Transform The Story
11/25/2025 - Seeking Alpha - Long Ideas
Septerna's Novo Partnership Begins To Transform The Story
11/25/2025 - SeekingAlpha
Septerna (SEPN) Is Up 9.9% After Swinging to Q3 Profit and Revenue Surge Has the Bull Case Changed?
11/23/2025 - Simply Wall St
Cantor Fitzgerald Sticks to Their Buy Rating for Septerna, Inc. (SEPN)
11/21/2025 - TipRanks Financial Blog
Septerna (NASDAQ:SEPN) Stock Price Up 6.7% - Here's Why
11/20/2025 - MarketBeat
Septerna price target raised by $6 at JPMorgan, here's why
11/18/2025 - The Fly
NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?
11/17/2025 - Zacks Investment Research
A Closer Look at Septerna (SEPN) Valuation Following Wave of Analyst Upgrades and Profitability Turnaround
11/17/2025 - Simply Wall St
Septerna (NASDAQ:SEPN) SVP Daniel Long Sells 3,501 Shares
11/16/2025 - MarketBeat
Septerna (SEPN) Is Up 25.7% After Turning Profitable on Strong Q3 Sales and Analyst Optimism Has The Bull Case Changed?
11/15/2025 - Simply Wall St
HC Wainwright Reduces Earnings Estimates for Septerna
11/15/2025 - MarketBeat
Daniel Long Sells 3,501 Shares of Septerna (NASDAQ:SEPN) Stock
11/14/2025 - MarketBeat
HC Wainwright Forecasts Septerna's Q4 Earnings (NASDAQ:SEPN)
11/14/2025 - MarketBeat
Septerna (SEPN) Receives Analyst Upgrade and Increased Price Target SEPN Stock News
11/14/2025 - GuruFocus
Septerna (SEPN) Stock Upgraded by Wells Fargo with Increased Price Target
11/14/2025 - GuruFocus
Wells upgrades Septerna to Overweight on 2026 share catalysts
11/14/2025 - TipRanks Financial Blog
Wells upgrades Septerna to Overweight on 2026 share catalysts
11/14/2025 - The Fly
Analysts Think These Stocks Could More Than Double in Value
5/23/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$22.05M
EBITDA (TTM)
-$87.90M
EBIT (TTM)
-$89.49M
Net Income (TTM)
-$58.81M
Balance Sheet
Total Assets (Q)
$606.65M
Total Debt (Q)
$24.11M
Total Liabilities (Q)
$217.92M
Book Value Per Share (Q)
$8.71
Cash Flow
Cash from Operations (TTM)
$104.22M
Cash from Investing (TTM)
-$177.29M
Cash from Financing (TTM)
$304.82M
Net Change in Cash (TTM)
$231.75M
Filings
Filing Date
Monday, November 10, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 23 and 27 (est)
Price History
Loading...
Beta
--
7-Day Total Return
2.39%
30-Day Total Return
22.81%
60-Day Total Return
71.94%
90-Day Total Return
89.23%
Year to Date Total Return
22.58%
1-Year Total Return
1.87%
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Feb 18, 2025 - $4.17
52-week High
Nov 26, 2025 - $29.74
Valuation
Market Cap
$1.17B - Small Cap
Enterprise Value
$634.29M
Price/Sales (TTM)
54.14
Price/Book (Q)
3.01
Dividends and Shares
Shares Outstanding
45.60
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
septerna.com
Phone Number
650 338 3533
Address
250 East Grand Avenue
South San Francisco, CA 94080
Country
United States
Year Founded
2019
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and... more
NASDAQ 12/02/2025 4:00PM Eastern Quotes delayed